Orbis Allan Gray LTD Crispr Therapeutics Ag Transaction History
Orbis Allan Gray LTD
- $18 Billion
- Q3 2025
A detailed history of Orbis Allan Gray LTD transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Orbis Allan Gray LTD holds 4,982,085 shares of CRSP stock, worth $262 Million. This represents 1.8% of its overall portfolio holdings.
Number of Shares
4,982,085
Previous 2,764,532
80.21%
Holding current value
$262 Million
Previous $134 Million
140.13%
% of portfolio
1.8%
Previous 0.88%
Shares
4 transactions
Others Institutions Holding CRSP
# of Institutions
545Shares Held
65.8MCall Options Held
3.5MPut Options Held
2.59M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl9.79MShares$514 Million4.45% of portfolio
-
Capital International Investors Los Angeles, CA5.65MShares$297 Million0.06% of portfolio
-
State Street Corp Boston, MA4.01MShares$210 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.28MShares$172 Million0.13% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$146 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.1B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....